Neoeriocitrin

Overview

Neoeriocitrin is a Naringin ( HY-N0153 ) analogue found in Drynaria Rhizome. Neoeriocitrin induces cells proliferation, differentiation, up-regulates type I collagen , osteocalcin, and key osteogenic markers, and increases ALP activity. Neoeriocitrin increases expression of Runx2 , COL I, OCN and Beclin1 . Neoeriocitrin inhibits phosphorylation of P38 mitogen-activated protein kinase , reduces acetylcholinesterase ( AChE ) activity, and increases choline acetyltransferase ( ChAT ) activity. Neoeriocitrin reduces apoptosis and induces autophagy . Neoeriocitrin can be used for the researches of osteoporosis and Alzheimer's disease.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Mineral Metabolism | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Osteoporosis | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Autophagy | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Phosphatase | Products > Signaling Pathways > Cholinesterase (ChE) | Products > Signaling Pathways > p38 MAPK

Product Information

• Catalog No.: HY-N4119
• CAS No.: 13241-32-2
• Molecular Formula: C27H32O15
• Molecular Weight: 596.53
• Purity: 99.97%
• Storage: -20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 2.5 mg/mL (4.19 mM); Clear solution
• Availability: In-stock

Source

Original product source